Promedior and Stromedix Spot Fresh Approaches in Fibrosis

New approaches to treating fibrotic disorders have led to start-up financing for Promedior and Stromedix, two biotechs with early-stage in-licensed large molecule programs. To succeed where others have so-far failed the two newcomers will need innovative clinical strategies to accelerate their paths to proof-of-concept.